Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo

European Journal of Dermatology

Volumn 15, Issue 2, 2005, Pages 88-91

  Coskun, Basak ^a   Saral, Yunus ^a   Turgut, Dilara ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Clobetasol proprionate; Pimecrolimus; Vitiligo

Indexed keywords

ASCOMYCIN; CALCINEURIN INHIBITOR; CLOBETASOL PROPIONATE; CORTICOSTEROID; MELANIN; PIMECROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; MALE; OINTMENT; PILOT STUDY; PROSPECTIVE STUDY; SCHOOL CHILD; SKIN ATROPHY; TELANGIECTASIA; VITILIGO;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; CHILD; CLOBETASOL; DERMATOLOGIC AGENTS; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; OINTMENTS; PROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME; VITILIGO;

EID: 15944426416     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine. 5th ed. New York: McGraw Hill, 1999: 949-60.
2. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493-503.
3. Marslond AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12(6): 618-22.
4. Luger T. Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 2001; 11(4): 343-7.
5. Mrowietz U. Mocrolide immunosuppressants. Eur J Dermatol 1999; 9(5): 346-51.
6. Hortmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004; 64: 89-107.
7. Moyoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207: 322-3.
8. Vancoillie G, Lambert J, Nayaert JM. Melanocyte biology and its implications for the clinician. Eur J Dermatol 1999; 9(3): 241-51.
9. Kostovic K, Nola I, Bucan Z, Situm M. Treatment of vitiligo: current methods and new approaches. Acta Dermatovenerol Croat 2003; 11: 163-70.
10. Bos JD. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol 2003; 13(5): 455-61.
11. Ongenoe K, Van Geel N, De Schepper S, Vander Haeghen Y, Naeyaert JM. Management of vitiligo patients and attitude of dermatologists towards vitiligo. Eur J Dermatol 2004; 14(3): 177-81.
12. Kumari J. Vitiligo treated with topical clobetasol propionote. Arch Dermatol 1984; 120: 631-5.
13. Geraldez CB, Gutierrez GT. A clinical trial of clobetasol propionate in Filipino vitiligo patients. Clin Ther 1987; 9: 474-82.
14. Clayton R. A double-blind trial of 0-05% clobetasol proprionate in the treatment of vitiligo. Br J Dermatol 1977; 96: 71-3.
15. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
16. Trovis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139: 571-4.
17. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91.
18. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205: 301-3.
19. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158-62.